Trial Profile
A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms Alliance
- 20 Jan 2024 Results assessing whether patients with TF-L tumors with liver metastases have improved prognosis compared to patients with TF-H and may benefit from FOLFOX and Cet-based treatment, presented at the 2024 Gastrointestinal Cancers Symposium
- 07 Jun 2022 Results examining the relationship between tumoral gene expression (GEx) of CYP27B1, VDR, and CYP24A and pt outcome in a study nested in this study, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Results (n=484) assessing gene expression levels of CDC37 have predictive values for anti-angiogenic therapies in mCRC patients using data from this trial and a regorafenib (regorafenib, Japanese retrospective cohort) presented at the 58th Annual Meeting of the American Society of Clinical Oncology